Compare iShares China Large-Cap ETF (FXI) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Herbalife Nutrition Ltd — how do they compare? iShares China Large-Cap ETF trades at $34.21 (market cap $3.86B), while Herbalife Nutrition Ltd trades at $12.89 (market cap $1.34B). The key difference: iShares China Large-Cap ETF is far larger — about 2.9× Herbalife Nutrition Ltd's market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Herbalife Nutrition Ltd for 43 Days on average.
| FXI | HLF | |
|---|---|---|
Market Cap | $3.86B | $1.34B |
Volume | 16,323,837 | 1,589,457 |
52-Week High | $41.08 | $19.96 |
52-Week Low | $31.59 | $7.75 |
Typical Hold Time | 150 Days | 43 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | $3.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.19, up 2.3% today, but technical indicators show a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent U.S.-China diplomatic engagement offers potential for reduced trade tensions, but momentum remains weak with the ETF trading near key support at $33.
FXI presents a value opportunity trading at half the S&P 500's P/E ratio with a 1.98% yield, but requires tolerance for significant geopolitical risk. The ETF's heavy financial sector exposure and China's export-driven economy face protectionism threats, making it suitable only for diversified portfolios with high risk tolerance.
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
